Resolving heterogeneity in first-episode and drug-naive major depressive disorder based on individualized structural covariance network: evidence from the REST-meta-MDD consortium

基于个体化结构协方差网络解决首发和未接受药物治疗的重度抑郁症的异质性:来自 REST-meta-MDD 联盟的证据

阅读:3

Abstract

BACKGROUND: Major depressive disorder (MDD) is a complex and heterogeneous disorder, and this heterogeneity poses a significant challenge for advancing precision medicine in patients with MDD. MRI-based subtyping analysis has been widely employed to address the heterogeneity of MDD patients. In this study, we investigated the subtypes of first-episode and drug-naive (FEDN) MDD patients based on the individualized structural covariance network (IDSCN). METHODS: In this study, we used T1-weighted anatomical images of 164 FEDN MDD patients and 164 healthy controls from the REST-meta-MDD consortium. The IDSCN of participants was obtained using the network template perturbation method. Subtypes of FEDN MDD were identified using k-means clustering analysis, and differences in neuroimaging findings and clinical symptoms between the identified subtypes were compared using two-sample t-tests. RESULTS: This study identified two subtypes of FEDN MDD: subtype 1 (n = 117) and subtype 2 (n = 47) by characterizing 10 edges that were significantly altered in at least 5% of patients (i.e., 8 patients) in the IDSCN. Compared with subtype 2, subtype 1 had significantly higher anxiety symptom scores, stronger structural covariance edges in 9 edges within the thalamus, and a significantly reduced gray matter volume (GMV) in the frontal and parietal regions, and in the thalamus. CONCLUSIONS: Our results suggest that patients with FEDN MDD can be classified into two different subtypes based on their IDSCN, providing an important reference for personalized treatment and precision medicine for patients with FEDN MDD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。